Drugs / pHIS-HIV-AE
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00333424 Comparator | Aug 2007 → Jul 2008 | HIV infectious disease | Kirby Institute | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pHIS-HIV-AE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00333424 ↗ |
| Modality | Vaccine | “Previously demonstrated safe and highly immunogenic in non-human primates, this study assessed DNA (pHIS-HIV-AE) prime, recombinant fowlpox (rFPV-HIV-AE) boost vaccines in humans.” PMID 20864808 ↗ Oct 2010 |
| Route | Intramuscular | “were administered intramuscularly at weeks 0, 4, 8 (6 mg pHIS-HIV-AE)” PMID 20864808 ↗ Oct 2010 |